ANTONIO RAFAEL
ANTELA LOPEZ
Profesor contratado doutor
Vicente
Estrada Pérez
Publicacións nas que colabora con Vicente Estrada Pérez (20)
2024
-
Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain
AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314
-
Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain
HIV Medicine
2022
-
Discovering HIV related information by means of association rules and machine learning
Scientific Reports, Vol. 12, Núm. 1
-
Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort
HIV Medicine, Vol. 23, Núm. 8, pp. 825-836
2021
-
COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study
HIV Medicine, Vol. 22, Núm. 9, pp. 867-876
-
Late presentation for HIV impairs immunological but not virological response to antiretroviral treatment
AIDS (London, England), Vol. 35, Núm. 8, pp. 1283-1293
-
Redefining therapeutic success in HIV patients: An expert view
Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518
2020
-
Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study
The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573
-
How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain
HIV Medicine, Vol. 21, Núm. 2, pp. 128-134
-
Risk of cardiovascular disease in patients with HIV infection undergoing antiretroviral therapy
Revista Clinica Espanola, Vol. 220, Núm. 3, pp. 149-154
2019
-
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
The Lancet, Vol. 393, Núm. 10167, pp. 143-155
-
Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, Vol. 39, Núm. 5, pp. 497-505
-
Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 6, pp. 373-379
-
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
The Lancet, Vol. 393, Núm. 10189, pp. 2428-2438
2016
-
Executive summary: Prevención y tratamiento de infecciones oportunistas y otras coinfecciones en pacientes infectados por el VIH: mayo de 2015
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 34, Núm. 8, pp. 517-523
-
Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013
Journal of Infection, Vol. 72, Núm. 5, pp. 587-596
-
Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 34, Núm. 8, pp. 516.e1-516.e18
-
Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy
JAMA - Journal of the American Medical Association, Vol. 316, Núm. 2, pp. 171-181
2012
-
Switching to raltegravir in virologically suppressed in HIV-1-infected patients: A retrospective, multicenter, descriptive study
Current HIV Research, Vol. 10, Núm. 8, pp. 673-678
2008
-
Patients' perception and effectiveness of a treatment containing enfuvirtide when used in HIV-infected patients without very advanced disease
HIV Clinical Trials, Vol. 9, Núm. 2, pp. 83-90